Connection

Jean-Charles Soria to Neoplasms

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Neoplasms.
Jean-Charles Soria
Connection Strength
1.882
Neoplasms
  1. Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? Eur J Cancer. 2020 09; 137:235-239.
    View in: PubMed
    Score: 0.112
  2. A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer. Eur J Cancer. 2020 06; 132:1-4.
    View in: PubMed
    Score: 0.110
  3. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Invest New Drugs. 2018 08; 36(4):619-628.
    View in: PubMed
    Score: 0.093
  4. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer. 2017 08; 81:142-150.
    View in: PubMed
    Score: 0.091
  5. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. Eur J Cancer. 2017 09; 83:185-193.
    View in: PubMed
    Score: 0.091
  6. [New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]. Med Sci (Paris). 2017 Jun-Jul; 33(6-7):563-564.
    View in: PubMed
    Score: 0.091
  7. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
    View in: PubMed
    Score: 0.090
  8. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79(6):1257-1265.
    View in: PubMed
    Score: 0.089
  9. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017 06; 7(6):586-595.
    View in: PubMed
    Score: 0.089
  10. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75.
    View in: PubMed
    Score: 0.071
  11. QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol. 2007 Apr; 30(2):106-12.
    View in: PubMed
    Score: 0.044
  12. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021 12; 28(12):3297-3315.
    View in: PubMed
    Score: 0.030
  13. Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1039-1041.
    View in: PubMed
    Score: 0.030
  14. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. ESMO Open. 2021 06; 6(3):100134.
    View in: PubMed
    Score: 0.029
  15. SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol. 2021 03; 22(3):298-301.
    View in: PubMed
    Score: 0.029
  16. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Glob Oncol. 2020 Sep; 6:1461-1471.
    View in: PubMed
    Score: 0.028
  17. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 05; 26(5):665-671.
    View in: PubMed
    Score: 0.027
  18. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clin Cancer Res. 2019 09 15; 25(18):5441-5448.
    View in: PubMed
    Score: 0.026
  19. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019 03; 109:103-110.
    View in: PubMed
    Score: 0.025
  20. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 12; 15(12):748-762.
    View in: PubMed
    Score: 0.025
  21. Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? Br J Cancer. 2018 10; 119(8):937-939.
    View in: PubMed
    Score: 0.025
  22. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
    View in: PubMed
    Score: 0.025
  23. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 11; 104:1-8.
    View in: PubMed
    Score: 0.025
  24. Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks? Eur J Cancer. 2018 11; 103:108-119.
    View in: PubMed
    Score: 0.025
  25. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018 09; 19(9):1180-1191.
    View in: PubMed
    Score: 0.024
  26. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
    View in: PubMed
    Score: 0.024
  27. Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer J. 2018 Jul/Aug; 24(4):153-162.
    View in: PubMed
    Score: 0.024
  28. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018 10 20; 36(30):3007-3014.
    View in: PubMed
    Score: 0.024
  29. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
    View in: PubMed
    Score: 0.024
  30. Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. Arch Cardiovasc Dis. 2018 Apr; 111(4):285-296.
    View in: PubMed
    Score: 0.024
  31. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018 02; 14(2):e1005965.
    View in: PubMed
    Score: 0.024
  32. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
    View in: PubMed
    Score: 0.024
  33. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
    View in: PubMed
    Score: 0.024
  34. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer. 2018 02 06; 118(3):344-352.
    View in: PubMed
    Score: 0.024
  35. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
    View in: PubMed
    Score: 0.023
  36. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017; 12(11):e0188174.
    View in: PubMed
    Score: 0.023
  37. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
    View in: PubMed
    Score: 0.023
  38. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 05; 359(6371):91-97.
    View in: PubMed
    Score: 0.023
  39. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
    View in: PubMed
    Score: 0.023
  40. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
    View in: PubMed
    Score: 0.023
  41. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep. 2017 08 11; 7(1):7952.
    View in: PubMed
    Score: 0.023
  42. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clin Cancer Res. 2017 Nov 01; 23(21):6411-6420.
    View in: PubMed
    Score: 0.023
  43. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. Eur J Cancer. 2017 09; 83:194-202.
    View in: PubMed
    Score: 0.023
  44. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017 Oct 15; 23(20):6101-6112.
    View in: PubMed
    Score: 0.023
  45. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
    View in: PubMed
    Score: 0.023
  46. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer. 2017 08; 81:81-89.
    View in: PubMed
    Score: 0.023
  47. Otorhinolaryngological Toxicities of New Drugs in Oncology. Adv Ther. 2017 04; 34(4):866-894.
    View in: PubMed
    Score: 0.022
  48. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res. 2016 Sep 01; 22(17):4309-21.
    View in: PubMed
    Score: 0.021
  49. Are phase I trials safe for older patients? J Geriatr Oncol. 2018 03; 9(2):87-92.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.